In addition, in this case, particular IL1B polymorphisms were significantly associated with the risk of IBD [75,76], conferring to the IL-1β drug silencing a potential therapy role, especially for patients caring these variants or for those with deep ulceration and who do not respond to several different current therapeutics [77]. Here, IL1B is linked to inflammatory bowel disease.